Barinthus Bio reports Phase 1b/2 VTP-200 trial: safety met but pooled efficacy not statistically significant

Barinthus Biotherapeutics plc.

APOLLO trial met primary safety endpoint; VTP-200 well-tolerated with no treatment-related Grade 3+ AEs or SAEs.
Highest hrHPV clearance 60% (group 2, highest ChAdOx dose) vs 33% placebo; cervical lesion clearance 67% (groups 2&5) vs 39% placebo.
Pooled data across all active dose groups showed no statistically significant improvement in hrHPV or cervical lesion clearance vs placebo.
Company evaluating future development options for VTP-200; further analyses ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.